News More 
  Home Â» News Â» Press Release


BETHESDA, MD - (June 2, 2004) . . . . Cardiac Science, Inc. (Nasdaq: DFIB), a leading manufacturer of life-saving automated public access defibrillators (AEDs), and Chindex International, Inc. (Nasdaq:CHDX), the leading independent American provider of western healthcare products and services in the People's Republic of China, jointly announced today a multi-year distribution agreement whereby Chindex will market Cardiac Science’s line of Powerheart® -brand AEDs on an exclusive basis to hospitals and other medical supply dealers throughout mainland China.

Powerheart® AEDs will be sold exclusively via Chindex' hospital sales business unit, which operates a network of more than 500 local area dealers located in both urban and rural centers throughout the country. The agreement also allows Chindex to distribute Cardiac Science AEDs on a non-exclusive basis into other emerging market segments such a physician offices, police, fire, EMS, military, corporations and public transportation.

Chindex President and CEO Roberta Lipson said that the AED market in China is quickly taking shape. Ms. Lipson expects the market to soon progress beyond hospitals and physician offices to first responder organizations and public places as it has in other industrialized nations.

"We believe this is an ideal partnership - a winning combination of distribution capabilities and quality products," said Lipson. "Chindex has been a well established player in the Chinese medical market for more than two decades. Our sales organization reaches deeply into the Chinese hospital system throughout the country -very few institutions have deployed AEDs. Given our distribution capabilities combined with Cardiac Science's quality products we believe we can gain a significant share of this emerging AED market. The success of Cardiac Science's AED product line in both in the U.S., Japan and other international markets is testament of the product’s ease of use, reliability and language capabilities as well as the Company's understanding of how to support their key distribution partners."

Cardiac Science Chairman and CEO Raymond W. Cohen said, "The healthcare market in China mirrors other Chinese industries in its rapid development and tremendous size. As we have demonstrated by gaining the number one market share position in Japan, the most important factor in an emerging international market is selecting the right strategic distribution partner. Chindex is amazingly well positioned to take advantage of growing demand for AEDs in the Chinese market. Clearly, we have made the right choice and we look forward to jointly developing this promising opportunity."

About Chindex International, Inc.
Chindex is a leading American company in healthcare in the Greater Chinese marketplace including Hong Kong. It provides representative and distribution services to a number of major multinational companies including Siemens AG (diagnostic color ultrasound scanners under the Acuson and Siemens brand names), Becton-Dickinson (including vascular access, infusion and critical care systems), Johnson & Johnson (clinical chemistry analyzers), and Guidant (interventional cardiology products including stents, balloon catheters and guide wires). Its distribution channels to the retail pharmacy industry in China have been developed through a relationship with a major multinational cosmetics manufacturer. It also provides healthcare services through the operations of its private hospital corporation in China. With twenty-two years of experience, over 700 employees, and operations in the United States, China and Hong Kong, Chindex's strategy is to expand its cross-cultural reach by providing leading edge technologies, quality products and services to Greater China's professional communities. Further information may be found at Chindex's websites, and

The statements in this press release that relate to Chindex’'s future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties pertaining to Chindex’''s(i) performance goals, including successful conclusion of efforts to secure government-backed financing, (ii) future events and earnings, including revenues from the Chindex’s developmental businesses such as healthcare services, (iii) markets, including growth in demand in China for the Chindex's products and services, and (iv) proposed new operations, including expansion of its healthcare services business. Actual results, events and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Chindex undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

About Cardiac Science
Cardiac Science develops, manufactures and markets the Powerheart ®-brand, automated public access defibrillators (AEDs) in over 50 countries worldwide. The Company also manufactures its AED products on a private-label basis for other leading medical companies. Cardiac Science is unique among AED manufactures in that it also offers comprehensive AED/CPR training and AED program management services for corporate and government clients that facilitate successful deployments. The Company’s also developed and markets Powerheart® CRM®, the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. For more information please visit or call 1.949.797.3800.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in Cardiac Science's Form 10-K for the year ended Dec. 31, 2003 and subsequent quarterly filings, and other documents filed by the Company with the Securities and Exchange Commission.


Copyright © 2002 Chindex International, Inc. All Rights Reserved